Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial
Authors:
Top Cited Papers
- 31 October 2019
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 394 (10212) , 1940-1948
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (P30DK072482, R35HL135816, U54TR001368)
This publication has 25 references indexed in Scilit:
- Better Nutritional Status in Early Childhood Is Associated with Improved Clinical Outcomes and Survival in Patients with Cystic FibrosisThe Journal of Pediatrics, 2013
- Ivacaftor in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR MutationChest, 2012
- Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equationsEuropean Respiratory Journal, 2012
- Correction of Both NBD1 Energetics and Domain Interface Is Required to Restore ΔF508 CFTR Folding and FunctionCell, 2012
- Requirements for Efficient Correction of ΔF508 CFTR Revealed by Analyses of Evolved SequencesCell, 2012
- Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosisEuropean Respiratory Journal, 2011
- A CFTR Potentiator in Patients with Cystic Fibrosis and theG551DMutationNew England Journal of Medicine, 2011
- Determination of the Minimal Clinically Important Difference Scores for the Cystic Fibrosis Questionnaire-Revised Respiratory Symptom Scale in Two Populations of Patients With Cystic Fibrosis and Chronic Pseudomonas aeruginosa Airway InfectionChest, 2009
- Dysfunction of CFTR bearing the AF508 mutationJournal of Cell Science, 1993
- Altered chloride ion channel kinetics associated with the ΔF508 cystic fibrosis mutationNature, 1991